{"id":9069,"date":"2022-02-17T16:36:38","date_gmt":"2022-02-17T21:36:38","guid":{"rendered":"https:\/\/type1support.ca\/faq-switching-to-biosimilar-insulins\/"},"modified":"2026-02-18T09:37:34","modified_gmt":"2026-02-18T14:37:34","slug":"faq-switching-to-biosimilar-insulins","status":"publish","type":"post","link":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/","title":{"rendered":"FAQ: switching to biosimilar insulins"},"content":{"rendered":"<p>In Quebec, most people who currently use one of the following original insulins: Lantus (Sanofi), Humalog (Lilly) or Novorapid (Novo Nordisk), are affected by the <a href=\"https:\/\/type1better.com\/en\/transition-to-biosimilar-insulin-products-does-it-concern-you\/\">Transition to Biosimilars<\/a>.<\/p>\n<p>Indeed, on April 13 (Lantus and Humalog) and July 6 (Novorapid), the &#8220;R\u00e9gie de l&#8217;Assurance Maladie du Qu\u00e9bec&#8221; (RAMQ) will stop reimbursing these insulins. Instead, the RAMQ will reimburse Biosimilar insulins of its original insulins.<\/p>\n<figure><a href=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/FAQ-Biosimilar.pdf\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"\" width=\"3882\" height=\"6000\" class=\"lazyload\" data-src=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Biosimilaires-1.png\"><\/a><\/figure>\n<p><a href=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/FAQ-Biosimilar.pdf\" download=\"\">Download<\/a><\/p>\n<figure><a href=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Lantus-vs-Basaglar-EN-1.pdf\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"\" width=\"3882\" height=\"6000\" class=\"lazyload\" data-src=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Lantus-vs-Basaglar-2.png\"><\/a><\/figure>\n<p><a href=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Lantus-vs-Basaglar-EN-1.pdf\" download=\"\">Download<\/a><\/p>\n<figure><a href=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Humalog-EN.pdf\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"\" width=\"1294\" height=\"2000\" class=\"lazyload\" data-src=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Humalog-vs-Admelog-EN.png\"><\/a><\/figure>\n<p><a href=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Humalog-vs-Admelog-EN-2.pdf\" download=\"\">Download<\/a><\/p>\n<figure><a href=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Novorapid-vs-Trurapi-EN-1.pdf\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"\" width=\"3882\" height=\"6000\" class=\"lazyload\" data-src=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Novorapid-vs-Trurapi-2.png\"><\/a><\/figure>\n<p><a href=\"https:\/\/type1better.com\/wp-content\/uploads\/2022\/02\/Novorapid-vs-Trurapi-EN-1.pdf\" download=\"\">Download<\/a><br \/>\n<a href=\"https:\/\/type1better.com\/en\/schedule\/\" target=\"_blank\" rel=\"noopener\"><\/p>\n<p><\/a><\/p>\n<p><a href=\"https:\/\/type1better.com\/en\/pdf\/\" target=\"_blank\" rel=\"noopener\"><\/p>\n<p><\/a><\/p>\n<h2>MORE TOOL?<\/h2>\n<p>Comparative tables of insulin pumps or continuous glucose monitors, products to use in case of allergy or detachment (sensor, catheter), adjustment of insulin doses, factors influencing blood glucose, examples of snacks, ketones, etc.<br \/>\n<a href=\"https:\/\/type1support.ca\/en\/actualites\/?filter_tag=pdf-files\">Discover our PDFs.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In Quebec, most people who currently use one of the following original insulins: Lantus (Sanofi), Humalog (Lilly) or Novorapid (Novo Nordisk), are affected by the Transition to Biosimilars. Indeed, on April 13 (Lantus and Humalog) and July 6 (Novorapid), the &#8220;R\u00e9gie de l&#8217;Assurance Maladie du Qu\u00e9bec&#8221; (RAMQ) will stop reimbursing these insulins. Instead, the RAMQ [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8031,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[4271],"tags":[4264],"class_list":["post-9069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diabetes-in-general","tag-articles-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FAQ: switching to biosimilar insulins - Support<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FAQ: switching to biosimilar insulins - Support\" \/>\n<meta property=\"og:description\" content=\"In Quebec, most people who currently use one of the following original insulins: Lantus (Sanofi), Humalog (Lilly) or Novorapid (Novo Nordisk), are affected by the Transition to Biosimilars. Indeed, on April 13 (Lantus and Humalog) and July 6 (Novorapid), the &#8220;R\u00e9gie de l&#8217;Assurance Maladie du Qu\u00e9bec&#8221; (RAMQ) will stop reimbursing these insulins. Instead, the RAMQ [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/\" \/>\n<meta property=\"og:site_name\" content=\"Support\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-17T21:36:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-18T14:37:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/type1support.naracreative.com\/wp-content\/uploads\/2025\/06\/Bannieres-de-blog-40.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2800\" \/>\n\t<meta property=\"og:image:height\" content=\"1350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Nara Creative\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nara Creative\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/\"},\"author\":{\"name\":\"Nara Creative\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#\\\/schema\\\/person\\\/2ff051523d648b019cff3909cdc91593\"},\"headline\":\"FAQ: switching to biosimilar insulins\",\"datePublished\":\"2022-02-17T21:36:38+00:00\",\"dateModified\":\"2026-02-18T14:37:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/\"},\"wordCount\":110,\"publisher\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/type1support.naracreative.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Bannieres-de-blog-40.png\",\"keywords\":[\"Articles\"],\"articleSection\":[\"Diabetes in general\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/\",\"url\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/\",\"name\":\"FAQ: switching to biosimilar insulins - Support\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/type1support.naracreative.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Bannieres-de-blog-40.png\",\"datePublished\":\"2022-02-17T21:36:38+00:00\",\"dateModified\":\"2026-02-18T14:37:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/#primaryimage\",\"url\":\"https:\\\/\\\/type1support.naracreative.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Bannieres-de-blog-40.png\",\"contentUrl\":\"https:\\\/\\\/type1support.naracreative.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Bannieres-de-blog-40.png\",\"width\":2800,\"height\":1350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/faq-switching-to-biosimilar-insulins\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/type1support.naracreative.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FAQ: switching to biosimilar insulins\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#website\",\"url\":\"https:\\\/\\\/type1support.naracreative.com\\\/\",\"name\":\"Type1Support\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/type1support.naracreative.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#organization\",\"name\":\"Type1Support\",\"url\":\"https:\\\/\\\/type1support.naracreative.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/type1support.ca\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/logo_support.png\",\"contentUrl\":\"https:\\\/\\\/type1support.ca\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/logo_support.png\",\"width\":253,\"height\":64,\"caption\":\"Type1Support\"},\"image\":{\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/type1support.naracreative.com\\\/#\\\/schema\\\/person\\\/2ff051523d648b019cff3909cdc91593\",\"name\":\"Nara Creative\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac453aae22aac79921ce5c9ff996f107abb65201217b31ffff4cca5d135a287d?s=96&d=https%3A%2F%2Ftype1support.ca%2Fdev%2Fwp-content%2Fuploads%2F2019%2F09%2Fapple.png&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac453aae22aac79921ce5c9ff996f107abb65201217b31ffff4cca5d135a287d?s=96&d=https%3A%2F%2Ftype1support.ca%2Fdev%2Fwp-content%2Fuploads%2F2019%2F09%2Fapple.png&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ac453aae22aac79921ce5c9ff996f107abb65201217b31ffff4cca5d135a287d?s=96&d=https%3A%2F%2Ftype1support.ca%2Fdev%2Fwp-content%2Fuploads%2F2019%2F09%2Fapple.png&r=g\",\"caption\":\"Nara Creative\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FAQ: switching to biosimilar insulins - Support","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"FAQ: switching to biosimilar insulins - Support","og_description":"In Quebec, most people who currently use one of the following original insulins: Lantus (Sanofi), Humalog (Lilly) or Novorapid (Novo Nordisk), are affected by the Transition to Biosimilars. Indeed, on April 13 (Lantus and Humalog) and July 6 (Novorapid), the &#8220;R\u00e9gie de l&#8217;Assurance Maladie du Qu\u00e9bec&#8221; (RAMQ) will stop reimbursing these insulins. Instead, the RAMQ [&hellip;]","og_url":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/","og_site_name":"Support","article_published_time":"2022-02-17T21:36:38+00:00","article_modified_time":"2026-02-18T14:37:34+00:00","og_image":[{"width":2800,"height":1350,"url":"https:\/\/type1support.naracreative.com\/wp-content\/uploads\/2025\/06\/Bannieres-de-blog-40.png","type":"image\/png"}],"author":"Nara Creative","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nara Creative","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/#article","isPartOf":{"@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/"},"author":{"name":"Nara Creative","@id":"https:\/\/type1support.naracreative.com\/#\/schema\/person\/2ff051523d648b019cff3909cdc91593"},"headline":"FAQ: switching to biosimilar insulins","datePublished":"2022-02-17T21:36:38+00:00","dateModified":"2026-02-18T14:37:34+00:00","mainEntityOfPage":{"@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/"},"wordCount":110,"publisher":{"@id":"https:\/\/type1support.naracreative.com\/#organization"},"image":{"@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/#primaryimage"},"thumbnailUrl":"https:\/\/type1support.naracreative.com\/wp-content\/uploads\/2025\/06\/Bannieres-de-blog-40.png","keywords":["Articles"],"articleSection":["Diabetes in general"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/","url":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/","name":"FAQ: switching to biosimilar insulins - Support","isPartOf":{"@id":"https:\/\/type1support.naracreative.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/#primaryimage"},"image":{"@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/#primaryimage"},"thumbnailUrl":"https:\/\/type1support.naracreative.com\/wp-content\/uploads\/2025\/06\/Bannieres-de-blog-40.png","datePublished":"2022-02-17T21:36:38+00:00","dateModified":"2026-02-18T14:37:34+00:00","breadcrumb":{"@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/#primaryimage","url":"https:\/\/type1support.naracreative.com\/wp-content\/uploads\/2025\/06\/Bannieres-de-blog-40.png","contentUrl":"https:\/\/type1support.naracreative.com\/wp-content\/uploads\/2025\/06\/Bannieres-de-blog-40.png","width":2800,"height":1350},{"@type":"BreadcrumbList","@id":"https:\/\/type1support.naracreative.com\/en\/faq-switching-to-biosimilar-insulins\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/type1support.naracreative.com\/en\/"},{"@type":"ListItem","position":2,"name":"FAQ: switching to biosimilar insulins"}]},{"@type":"WebSite","@id":"https:\/\/type1support.naracreative.com\/#website","url":"https:\/\/type1support.naracreative.com\/","name":"Type1Support","description":"","publisher":{"@id":"https:\/\/type1support.naracreative.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/type1support.naracreative.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/type1support.naracreative.com\/#organization","name":"Type1Support","url":"https:\/\/type1support.naracreative.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/type1support.naracreative.com\/#\/schema\/logo\/image\/","url":"https:\/\/type1support.ca\/wp-content\/uploads\/2025\/03\/logo_support.png","contentUrl":"https:\/\/type1support.ca\/wp-content\/uploads\/2025\/03\/logo_support.png","width":253,"height":64,"caption":"Type1Support"},"image":{"@id":"https:\/\/type1support.naracreative.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/type1support.naracreative.com\/#\/schema\/person\/2ff051523d648b019cff3909cdc91593","name":"Nara Creative","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ac453aae22aac79921ce5c9ff996f107abb65201217b31ffff4cca5d135a287d?s=96&d=https%3A%2F%2Ftype1support.ca%2Fdev%2Fwp-content%2Fuploads%2F2019%2F09%2Fapple.png&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ac453aae22aac79921ce5c9ff996f107abb65201217b31ffff4cca5d135a287d?s=96&d=https%3A%2F%2Ftype1support.ca%2Fdev%2Fwp-content%2Fuploads%2F2019%2F09%2Fapple.png&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ac453aae22aac79921ce5c9ff996f107abb65201217b31ffff4cca5d135a287d?s=96&d=https%3A%2F%2Ftype1support.ca%2Fdev%2Fwp-content%2Fuploads%2F2019%2F09%2Fapple.png&r=g","caption":"Nara Creative"}}]}},"category_colors":{"4271":"#978bfc"},"_links":{"self":[{"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/posts\/9069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/comments?post=9069"}],"version-history":[{"count":0,"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/posts\/9069\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/media\/8031"}],"wp:attachment":[{"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/media?parent=9069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/categories?post=9069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/type1support.naracreative.com\/en\/wp-json\/wp\/v2\/tags?post=9069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}